Biotech entity
Every one of those 1 sits in a single category, pharma. RECCE® 327 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. RECCE® 327 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. We currently track 1 Biotech story that mention RECCE® 435, all published on March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RECCE® 435. Shared-story counts are live from our verified record — not editorial picks.
Recce Pharmaceuticals has been granted a pivotal patent in Brazil for its proprietary synthetic anti-infectives platform, marking a strategic expansion into South America's largest healthcare market. This intellectual property milestone strengthens the company's global protection for its novel class of broad-spectrum antibiotics designed to combat the escalating threat of antimicrobial resistance.
RECCE® 435 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
